News
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...
Novo Nordisk is facing an unprecedented crisis of confidence as the tumble in its valuations reached extremely fearful levels ...
Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...
Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results